Project Grant R41AG090217
Award Date 9/15/25
Completion Date 8/31/26
Dollars Obligated $506K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Kentucky, USA
Similar Awards
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund the development of a novel Alzheimer's disease therapeutic using targeted nanoparticles. The $504,732 award to Aphios Corp, a minority-owned biotechnology company, will support two phases of research. In Phase I, the company will nanoencapsulate an anti-CCR5 drug in targeted and non-targeted nanoparticles, characterize the formulations, and evaluate their impact on in vitro models of brain...
- The National Institute on Aging (NIA) awarded a $949,062 Project Grant (CFDA 93.866) to Somatoceutics LLC to develop a non-toxic, peptide-based nanomaterial (SMC-101 nanotubes) for delivering drugs across the blood-brain barrier to treat Alzheimer's disease and other dementias. The objectives are to optimize the nanotubes for drug-loading and transcytosis across a blood-brain barrier model in vitro, and then evaluate their toxicity and ability to deliver the drug galantamine to the central...
- This Project Grant award of $475,014.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop a novel neurotrophic therapeutic for treating the cognitive deficits associated with Alzheimer's disease. The key products and services to be delivered through this grant include: Scaling up the production of a recombinant, non-erythropoietic neurotrophic protein that has demonstrated cognitive enhancement effects in Alzheimer's disease models. Evaluating the toxicity...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $499,588 to develop non-radioactive nanoprobes for magnetic resonance imaging (MRI) of tropomyosin receptor kinase B (TrkB) in Alzheimer's disease. The goal is to create new MRI-based imaging tools to detect reduced TrkB expression, which is linked to impaired neurogenesis, synaptic damage, and neuronal death in Alzheimer's. The award recipient, Exqor Technologies Inc., will work to create a...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $994,436.00 to Transchromix LLC to develop novel brain-penetrant drugs for treating Alzheimer's disease (AD). The key products and services being delivered include: Discovering a noncanonical, translation regulatory function of the histone methyltransferase G9A in AD pathogenesis using a chromatin-activity-based chemoproteomic (ChAC) approach to dissect AD heterogeneity. Deducing the mechanism...
- The National Institute on Aging (CFDA 93.866) awarded a $513,740 Project Grant to President and Board of Trustees of Santa Clara College to develop a novel exosome-based nano-scavenger (EBNS) for the targeted removal of amyloid-beta proteins, which are a key characteristic of Alzheimer's disease. The 3-year project aims to genetically engineer exosomes to load both amyloid-targeting antibodies and amyloid-degrading enzymes, leveraging the intrinsic tissue-penetrating abilities of exosomes as a...
- The National Institute on Aging (NIA), part of the U.S. Department of Health and Human Services, awarded a $1,249,957 Project Grant under CFDA 93.866 (Aging Research) to Advantage Therapeutics, Inc. in Florida. The grant aims to perform IND-enabling studies on a small molecule that is disease-modifying, low-cost, and has a long safety record for the treatment of Alzheimer's disease. The proposed molecule is designed to reduce brain inflammation and restore phagocytosis, thereby improving the...
- This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $499,441 to Acepre, LLC to develop a novel brain-targeted delivery system for the compound N-acetylcysteine (TN-NAC) as a potential treatment for Alzheimer's disease (AD). The key objectives of this Phase I STTR study are to: 1) evaluate the toxicity and pharmacokinetic properties of TN-NAC in mice, and 2) test the therapeutic efficacy of TN-NAC in a 3xTG-AD mouse model of...
- This federal Project Grant award of $835,417, provided by the National Institute on Aging (CFDA 93.866 - Aging Research), aims to develop novel lipid nanoparticle (LNP) formulations for the delivery of nucleic acid therapeutics to the brain for the treatment of Alzheimer's disease (AD). The key objectives include: 1) synthesizing novel blood-brain barrier (BBB)-crossing lipids, 2) formulating a library of LNPs, and 3) elucidating their trafficking pathways across the BBB. Additionally, the...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $500,000.00 to Alzarrok Bio LLC to develop a peptide-based multi-target drug for Alzheimer's disease (AD). The goal is to demonstrate the in vivo efficacy of the drug candidate, ALZ100, in inhibiting neuroinflammation and neurodegeneration in an AD mouse model. The project will first determine the therapeutic concentration of ALZ100 in the brain and then evaluate its effects on key...